Skip to main content

Phase 1 cancer trials

What is a Phase 1 cancer trial?

A Phase 1 trial is usually the first study of a new cancer treatment in people. It is built around safety, side effects, and finding the right dose, not around proving the treatment works better than what is already used. Phase 1 trials are small, often about 15 to 30 people, and participants are watched closely for unexpected side effects.

This is not clinical evidence and not medical advice. It does not replace your care team. Discuss anything here with your clinician before you act on it. Product questions are on the FAQ.

Made by Triangle.

Safety, dose, how many people, how closely they are watched. Not a test of whether the treatment works.

Does joining a Phase 1 trial mean standard care has failed?

Not automatically. Eligibility is written into the protocol. Some trials enrol people after standard options; others enrol earlier, in narrower settings. Read that on the ClinicalTrials.gov listing, with your care team.

How many people are in a Phase 1 cancer trial?

Small groups, typically around 15 to 30. Later phases grow: roughly 50 to 100 in Phase 2, and from a hundred to several thousand in Phase 3.

How closely are people watched in a Phase 1 trial?

Closely. Participants are monitored for unexpected side effects. If a safety concern comes up, the study is paused and examined. An institutional review board reviews the protocol before enrolment and at least yearly after that.

Can I join a Phase 1 trial if I've had brain metastases, am older, or have HIV or hepatitis?

It depends on that trial's protocol. A November 2026 FDA draft guidance does not change those criteria on its own. The draft covers early-phase trials in solid tumors, not blood cancers, and it is not binding on FDA or the public. In the draft, FDA says unnecessarily restrictive eligibility criteria may slow enrolment, limit access to early-phase trials, and make the results less applicable to the people who will ultimately use the drug. It says that, in general, protocols should not impose upper age limitations, and that if one is proposed, adequate justification should be provided. It says thoughtful consideration should be given to the potential inclusion of people with brain metastases, while maintaining adequate patient safety, and of people with HIV, hepatitis B, or hepatitis C. Unless scientifically justified or necessary for the study's goals, FDA generally does not recommend time-based wash-out periods. Eligibility after a prior treatment should be based on recovery from clinically significant side effects. You can ask the study team whether a given exclusion is required for this drug.

See recruiting clinical trials →

Sources

For you, or someone you love

Ask this about your own records.

Triangle brings your medical records, genetic results and wearables into one place that you control, with your records organised by condition. Ask about your own file in plain language, and walk into every appointment knowing what to ask.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks, next to your genetic results and wearables. Add scans and anything on paper.

  • Read in plain words

    Reports explained as they come in, organised by condition, with lab values you can follow over time.

  • Ready for every appointment

    Ask about your own file, and walk in knowing what to ask your doctors.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.